Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nutmeg extract (NEMM) is a topical botanical formulation developed by researchers at the Faculty of Medical Sciences, University of the West Indies, for the treatment of painful diabetic neuropathy (PDN). The preparation consists of a combination of mace oil (2%), nutmeg oil (14%), methyl salicylate (6%), menthol (6%), and coconut oil. It is designed to alleviate neuropathic pain through the analgesic and counter-irritant properties of its components, specifically menthol's action on TRPM8 receptors and methyl salicylate's inhibition of cyclooxygenase (COX) enzymes. In a randomized, double-blind, placebo-controlled trial involving 74 subjects, the extract did not demonstrate significant clinical benefit over a 4-week period compared to preparations containing only menthol and methyl salicylate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nutmeg extract.